Dr Lal Pathlabs Ltd

With a decisive intraday surge to Rs 2035, Dr Lal Pathlabs Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This achievement comes amid a backdrop of strong technical signals that have aligned to propel the stock beyond previous resistance levels.

Dr Lal Pathlabs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 July 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 08 September 2026, providing investors with the most up-to-date view of the company’s performance and prospects.

Dr Lal Pathlabs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Dr Lal Pathlabs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 August 2026, providing investors with the latest insights into its performance and outlook.

With a decisive surge to Rs 1989.35 on 12 Aug 2026, Dr Lal Pathlabs Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained outperformance relative to the broader market.

Surpassing the Rs 1970 mark for the first time, Dr Lal Pathlabs Ltd has reached a fresh 52-week high on 10 Aug 2026, propelled by a confluence of bullish technical indicators and sustained price momentum. This milestone caps a year-long rally that has delivered a 23.16% return, comfortably outpacing the Sensex’s decline of 1.83% over the same period.

Dr Lal Pathlabs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 July 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 06 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Surging past its previous peaks, Dr Lal Pathlabs Ltd touched a fresh 52-week high of Rs 1950.45 on 4 Aug 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained outperformance relative to its sector and the broader market.

With a decisive breakthrough to Rs 1939, Dr Lal Pathlabs Ltd has reached a fresh 52-week high, marking a 52.3% rise from its low of Rs 1272 over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price trends, even as the broader Sensex showed signs of losing steam after an initial gap-up opening.

With every major technical indicator aligned to the upside, Dr Lal Pathlabs Ltd surged to a fresh 52-week high of Rs 1910 on 30 Jul 2026, marking a significant milestone in its price momentum journey.

Dr Lal Pathlabs Ltd (LALPATHLAB) emerged as one of the most actively traded stocks by value on 27 Jul 2026, registering a robust 6.41% gain and hitting a new 52-week high of Rs 1894.9. The healthcare services company’s strong performance was underpinned by significant institutional participation, elevated delivery volumes, and a sustained upward price momentum that outpaced both its sector and the broader market indices.

Surging to an intraday peak of Rs 1893.65 on 27 Jul 2026, Dr Lal Pathlabs Ltd has marked a fresh 52-week high, extending its upward momentum amid a backdrop of robust technical signals and steady market conditions.

The Sensex advanced 0.81% on 27 Jul 2026, yet Dr Lal Pathlabs Ltd outpaced the broader market with a 7.47% gain, reaching a fresh 52-week high of Rs 1893.65. This 7.05 percentage-point outperformance over its Healthcare Services sector peers highlights a distinctly stock-specific rally rather than a mere market tailwind.

Dr Lal Pathlabs Ltd has demonstrated a marked improvement in its financial performance for the quarter ended June 2026, prompting MarketsMOJO to upgrade its rating from Hold to Buy. The healthcare services company posted record quarterly figures across key metrics, signalling a positive shift in its growth trajectory and operational efficiency.

Dr Lal Pathlabs Ltd is rated Buy by MarketsMOJO, with this rating last updated on 24 July 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 26 July 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.

Dr Lal PathLabs Ltd., India's leading diagnostic services provider, reported a robust Q1 FY27 performance with consolidated net profit surging 28.02% year-on-year to ₹169.50 crores, marking its highest-ever quarterly profit. The results, announced for the quarter ended June 2026, demonstrate the company's strong operational momentum with revenue growth of 19.10% YoY to ₹797.70 crores and operating margins expanding to 31.03%. Following the announcement, the stock rallied 4.15% to close at ₹1,756.70, pushing the company's market capitalisation to ₹28,027 crores.